RNA sequencing analysis demonstrated that the pharmacological suppression of IRP2 by KS-20226 resulted in the downregulation of mitochondrial gene modules, DNA repair, and G2/M checkpoint gene sets in various BC cell lines, a conclusion corroborated by assessments of mitochondrial function and the cell cycle. The gene discussed is IREB2; the disease is breast cancer.